The genetic mutation given to Chinese twins last year rendering them immune to the HIV virus may significantly reduce life expectancy, scientists said Monday in a fresh warning against human gene-editing.
Chinese researcher He Jiankui last year provoked widespread outrage among doctors by unveiling the results of an experiment he conducted to alter the DNA of twin girls, prompting authorities in Beijing to announce a moratorium on the practice.
He used a gene-editing tool known as Crispr to insert a mutated variant of a CCR5 gene -- known as Delta32 -- into the girls' chromosome at the embryo stage meaning they are now immune to the AIDS-causing HIV virus.
But a new wide-ranging study of genetic make-up and death registry information suggests individuals carrying the D32 mutation face a 20-per cent higher risk of early death compared with the global population.
Researchers from the University of Berkeley California examined the health data of 409,000 people of British ancestry and looked at whether or not they possessed the mutation, which occurs naturally in around one percent of the population, and how and when they died.
After correcting for the ages of those involved, they found those with the mutation were 21 per cent more likely to die before the age of 76 than those who did not.
They found that D32 possessors were significantly more likely to die from diseases that are far more common than HIV, notably influenza.
"The cost of resistance to HIV may be increased susceptibility to other, and perhaps more common, diseases," the study's authors wrote.
The research, published in the journal Nature Medicine, doesn't explain why the mutation increases mortality risk, but the authors said there was a clear statistical trend that should discourage repeats of He's experiment.
"Introduction of new or derived mutations in humans using Crispr technology... comes with considerable risk even if the mutations provide a perceived advantage," they said.
China in November it said had ordered people involved in the twin experiment to halt their activities, ruling that it "seriously violates" national law and medical ethics.
David Curtis, honorary Professor at University College London's Genetics Institute, said the new study provided a clear look at the possible unintended consequences of gene-editing in humans.
"There are many other examples in medicine where an intervention intended to treat one condition inadvertently causes major unexpected problems elsewhere," said Curtis, who was not involved in the study.
"This sends us a warning that we should be extremely cautious around the introduction of therapies involving modifying the genetic code."
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
